Scientific Publications Database

Article Title: Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia
Authors: Visram, Alissa; Aziz, Joseph; Bryant, Adam; Zhang, Tinghua; Cieniak, Carolina; Hamelin, Linda; Landry, Carey; Morris, Gail; Mercer, Dena; Atkins, Harold; Huebsch, Lothar; Al-Touri, Sultan; Fulcher, Jill; Sabloff, Mitchell; Kekre, Natasha; Bredeson, Christopher; Allan, David
Journal: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION Volume 24 Issue 12
Date of Publication:2018
Abstract:
Relapse after allogeneic hematopoietic cell transplantation (HCT) for acute leukemia can be reduced when pursued early after first complete remission. The impact of donor age and donor relatedness on the time from diagnosis to transplant in patients with acute leukemia was examined to clarify the design of future prospective studies that can address optimal donor choice. Files of 100 consecutive patients undergoing transplantation for leukemia were reviewed. Recipients of related donors (RDs) and unrelated donors (UDs) were not significantly different in terms of recipient gender, age, underlying diagnosis, disease risk index, graft source, or donor HLA match. UDs were significantly younger than RDs (median age, 29 versus 51, P < .001). Multivariate linear regression revealed that when controlling for age of donor and recipient, the time from diagnosis to transplant was 35% longer with UDs compared with RDs (P =.018). No significant correlation was observed between donor and recipient age on length of time to transplant (P = .134 and p=.850, respectively), when controlling for other variables. The steps in UD procurement that contribute most to the longer time to transplant relate to activating the donor workup and scheduling the donor workup before cell collection. Understanding sources of delay in the transplant process will help transplant centers and UD registries reduce the time to transplant for patients with acute leukemia and will provide necessary insight for the design of prospective controlled studies that can address optimal donor choice. (C) 2018 American Society for Blood and Marrow Transplantation.